Intercytex to use BioLife's HypoThermosol in cellular therapy trials

08/26/2013 | Pharmaceutical Business Review Online

BioLife Solutions' cell and tissue storage/shipping medium HypoThermosol will be used in ongoing clinical studies of Intercytex's cell-based treatment ICX-RHY-013 in patients with burn injuries and recessive dystrophic epidermolysis bullosa in the U.S. and Europe. HypoThermosol will be used as the delivery solution for therapeutic cells and as the placebo in the control group.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA